Surveillance Workgroup Q3-2015 Update
The SRV-WG is defining the magnitude and trends of drug resistance in high burden countries, with particular focus on new and existing drugs for which resistance surveillance data are largely unavailable. Furthermore, the development of novel strategies for surveillance of TB drug resistance based on high-throughput molecular technologies will be explored.
- Facilitate the production of surveillance data on resistance to new and selected existing drugs.
- Validate high-throughput molecular methods for surveillance of drug resistance.
- Develop a glossary of terms and standardized language for drug-resistant surveillance.
- Lead the development of a TB drug sequencing data platform.
- A concept sheet and participant list for the standardization of reporting language for TB molecular diagnostics workshop, scheduled for February 3-4, 2016, was approved. The distribution of invitations will be completed later in 2015. Focused discussions and finalization of the workshop agenda is underway.
- A list of WHO standardized definitions concerning clinical outcomes to be included in the ReSeqTB Platform is under final review.
- WHO has finished the first phase of the geno/pheno project for PZA and FQ with five representative countries (Azerbaijan, Belarus, Pakistan, Bangladesh and South Africa). This work is being drafted as a manuscript.
- WHO is continuing with a second funded project to correlate the geno/pheno profiles of Rifampin and Isoniazid. The collection of whole genome sequencing data in the initial 5 countries (listed in previous bullet) will be complete by end in 2015. The number of countries is expanding to include the Ukraine (August) and the Philippines (October). Continuing to correlate the geno/pheno profiles of Rifampin and Isoniazid.